LEUKOCARE and Boehringer Ingelheim enter into a license agreement in the field of veterinary diagnostics


LEUKOCARE grants a license to Laboratorios Liomont
Biotechnology company LEUKOCARE AG, Germany, and Laboratorios Liomont S.A., Mexico, have entered into a license agreement in the field of biosimilar development. Under the terms of this agreement, Liomont will have access to LEUKOCARE´s SPS® technology platform and know-how to develop a novel ­formulation for one of Liomont’s pharmaceutical products.

Biotechnology company LEUKOCARE has gained another important partner for its Stabilizing and Protecting Solutions (SPS®) technologies. As the company from Martins­ried near Munich announced, LEUKOCARE has signed a license agreement with ­Boehringer Ingelheim. Based on this agreement, the animal health division of pharmaceutical company Boehringer Ingelheim will use LEUKO­CARE’s SPS® formulation techno­logies to deploy and stabilize biological reagents in a new veterinary diagnostics ­pro­duct. License and payment terms have not been disclosed by the partners.


Michael Scholl, CEO, LEUKO­CARE

Michael Scholl, CEO of LEUKOCARE, commented: “After having worked with ­Boehringer Ingelheim for a long time and being closely involved in their development activities, we are very pleased to be able to support our partner with our SPS® techno­logies in a specific application. This demonstrates once again the high quality of our SPS® formulation technology platform as well as our development expertise.